D. E. Shaw & Co., Inc. Glycomimetics Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.9 $112,966 - $184,853	-205,393 Reduced 84.87%	36,630 $20,000
Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.15 $7,376 - $15,710	-13,661 Reduced 5.34%	242,023 $144,000
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $12,187 - $19,255	-12,187 Reduced 4.55%	255,684 $291,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.14 $70,437 - $104,678	-48,915 Reduced 15.44%	267,871 $385,000
Q3 2021 Nov 15, 2021	BUY	$1.8 - $2.39 $92,367 - $122,642	51,315 Added 19.33%	316,786 $694,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $540,922 - $796,357	-250,427 Reduced 48.54%	265,471 $616,000
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $178,391 - $260,487	-61,727 Reduced 10.69%	515,898 $1.55 Million
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $462,432 - $728,889	171,908 Added 42.37%	577,625 $2.17 Million
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $19,690 - $32,070	6,414 Added 1.61%	405,717 $1.25 Million
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $424,405 - $774,642	206,022 Added 106.59%	399,303 $1.5 Million
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $210,651 - $622,745	115,110 Added 147.25%	193,281 $440,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $116,745 - $188,298	28,969 Added 58.88%	78,171 $414,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $137,765 - $632,245	49,202 New	49,202 $212,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $159,145 - $208,748	-10,878 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $2.27 Million - $3.59 Million	-141,602 Reduced 92.87%	10,878 $177,000
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $1.6 Million - $2.63 Million	152,480	152,480 $2.56 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account